Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

P. Gosse | S. Oparil | Pankaj Gupta | G. Grassi | A. Oliveras | Ji-Guang Wang | J. Powell | G. Bakris | J. Václavík | Y. Sharabi | N. Aslam | A. Kroon | C. Yosefy | J. Widimský | R. Cífková | Z. Gaciong | J. Redón | A. Więcek | Karl Pettis | F. Mcgrew | M. Volpe | K. Narkiewicz | M. Esler | A. Wilkołaski | O. Ormezzano | A. Ajani | S. Taddei | A. Peace | F. Veglio | O. Ukkola | F. Mahfoud | C. Ott | A. Januszewicz | P. Lurz | J. Flack | M. Azizi | D. Colquhoun | P. Diller | M. Soucek | J. Mooney | V. Tseluyko | P. Velásquez-Mieyer | I. Kantola | G. Dresser | Joong-il Park | K. Tsioufis | Y. Sirenko | J. Deinum | M. Schlaich | J. Krzesinski | A. Tykarski | J. Stegbauer | S. Biswas | A. Konradi | M. Vallée | J. Neutel | Konstantin Nikolaev | S. Roger | R. Nambiar | J. Son | T. Backer | J. Tartière | D. Scott | Katalin Bezzegh | M. Koziolek | P. Delsart | A. Persu | P. Courand | P. Zebekakis | F. Martinez | Ying-qing Feng | M. Chaumont | Marianna Zsom | S. Atar | B. Born | O. Karpenko | M. Kushnir | F. Merali | A. Manolis | M. Elias | E. Kosmacheva | T. Pecherina | J. Pritchard | G. Elder | A. Karavidas | Hae-Young Lee | L. Haskell | P. Toth | Chang Hoon Lee | S. Arora | N. Petrochenkova | A. Obrezan | S. Patsilinakos | M. El-Shahawy | C. Mercado | Xin Zhang | Jing Yu | L. Rich | D. Collier | G. Girard | Mark Warren | R. Busch | A. Kleinrok | J. Mu | J. Marcinkeviciene | I. Woźniak | D. Brautigam | M. Chrostowska | I. Katz | J. Taurio | J. Walczewska | V. Shatylo | B. Rewerska | N. Andrawis | I. Rychlík | M. Bellet | R. Raugaliene | S. Chow | M. Stanislavchuk | D. Calhoun | Shivinder Jolly | P. Danaietash | Nashwa Gabra | Michael Bauer | A. Yagensky | Hong Yuan | V. Tyrenko | L. Pliamm | A. Jamal | Nicole Toursarkissian | Michael A. Weber | Ji-Gwang Wang | J. Tartiere | I. Ler | G. Kania | R. Schmieder | David Webb | W. R. Davis | Y. Paliwal | R. Sangrigoli | K. Kyfnidis | G. Skoczylas | L. Rudenko | I. Kenis | A. Kuzin | Yu. V. Shvarts | V. Mordovin | J. Kumar | S. Gouge | Paramjit Kalirao | Dennis M Tang | Yu.Yu. Rudyk | T. Lewis | Ahmed K. Awad | Jang-Young Kim | Pascal Dabel | Jianhong Xie | G. Kamalov | J. Krekora | R. Bhagwat | Will Eaves | László Kovács | R. F. Dreier | M. Sassi-Sayadi | C. Reid | Thomas Vanabsche | E. Schiffrin | Ling Lin | Martin Ullrych | M. Lukac | T. G. Lauridsen | Páll Dénes | Ivetta Sukholutsky | Muiesan Maria Lorenza | R. Kavaliauskiene | Anna Podrazka-Szczepaniak | Cezary Goławski | Maciej Podziewski | B. Kaczmarek | Marzena Janik-Palazzolo | Gapon Liudmila | O. Orlikova | V. Gorbunov | T. Supryadkina | O. Kotenko | Luis Beltran Romero | A. Bazylevych | E. Asanov | M. MacLeod | James McLay | Patricia Buchanan | Robert Harris | R. Degarmo | Mario Guillen | Adam Karns | Jeffrey M. Wayne | B. Butcher | Jesse Goldman | A. Rashidi | William Haley | B. Lang | Randy L. Miller | R. Dewhurst | D. Khanna | Jean-Ho Park | Conigliaro Jones | C. Scott | B. Luna | Murtaza Mussaji | J. McGinty | E.J. Bolster | Wesley Calhoun | M. K. Lawrence | Dennis M. Tang | Jyrki Taurio | K. Nikolaev | M. Bauer | Jianhong Xie | L. Kovács | K. Tsioufis | P. Delsart | Mouna Sassi-sayadi | Valerii Shatylo | N. Andrawis

[1]  Ji-Guang Wang,et al.  Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan , 2022, Journal of clinical hypertension.

[2]  M. Clozel.  Aprocitentan and the endothelin system in resistant hypertension. , 2022, Canadian journal of physiology and pharmacology.

[3]  L. Brant,et al.  The Burden of Resistant Hypertension Across the World , 2022, Current Hypertension Reports.

[4]  Gretchen A. Stevens,et al.  Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants , 2021, The Lancet.

[5]  R. Collins,et al.  Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis , 2021, The Lancet.

[6]  J. Dingemanse,et al.  Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans. , 2021, Current drug metabolism.

[7]  Guilherme C. Salles,et al.  Prognostic Importance of On-Treatment Clinic and Ambulatory Blood Pressures in Resistant Hypertension , 2020, Hypertension.

[8]  J. Ménard,et al.  Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension , 2020, Hypertension.

[9]  Debra F. Weinstein,et al.  Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. , 2019, Lancet.

[10]  J. Dingemanse,et al.  Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects , 2019, Drug design, development and therapy.

[11]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension]. , 2019, Kardiologia polska.

[12]  David A Calhoun,et al.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. , 2018, Hypertension.

[13]  J. R. Nansseu,et al.  Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients , 2018, Heart.

[14]  M. Caulfield,et al.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial , 2015, The Lancet.

[15]  G. Bakris,et al.  The double challenge of resistant hypertension and chronic kidney disease , 2015, The Lancet.

[16]  G. Zoppini,et al.  Resistant hypertension in patients with type 2 diabetes: clinical correlates and association with complications , 2014, Journal of hypertension.

[17]  M. Woodward,et al.  Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data , 2014, The Lancet.

[18]  N. Dhaun,et al.  Endothelin‐1 and the kidney – beyond BP , 2012, British journal of pharmacology.

[19]  P. Sager,et al.  Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial , 2010, Hypertension.

[20]  B. Wiens,et al.  A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.

[21]  A. Mitchell,et al.  Avosentan reduces albumin excretion in diabetics with macroalbuminuria. , 2009, Journal of the American Society of Nephrology : JASN.

[22]  D. Webb,et al.  Role of endothelin-1 in clinical hypertension: 20 years on. , 2008, Hypertension.

[23]  Amanda Dudley,et al.  Influence of albuminuria and glomerular filtration rate on blood pressure response to antihypertensive drug therapy , 2007, Vascular health and risk management.

[24]  Alice Stanton,et al.  Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting Mortality: The Dublin Outcome Study , 2005, Hypertension.

[25]  M. Nieminen,et al.  Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study , 2005, Hypertension.

[26]  A. Ergul,et al.  Saphenous Vein Endothelin System Expression and Activity in African American Patients , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[27]  E. Pfarr,et al.  Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. , 2002, American journal of hypertension.

[28]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[29]  H. Krum,et al.  The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. , 1998, The New England journal of medicine.

[30]  S. Corrao,et al.  Central obesity and hypertension: the role of plasma endothelin. , 1995, American journal of hypertension.

[31]  K. Takahashi,et al.  Elevated plasma endothelin in patients with diabetes mellitus , 1990, Diabetologia.

[32]  V. Somers,et al.  Effects of obstructive sleep apnea on endothelin-1 and blood pressure. , 1999, Journal of hypertension.